METex14 NSCLC is highly heterogenous, with variations in co-mutation, TMB, and PD-L1 expression. Although Sq- and nSq-NSCLC harbor METex14, the enrichment of oncogenic pathways and infiltrating immune cells differ between histology and smoking history.

over 1 year ago

Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CDK4 (Cyclin-dependent kinase 4) • RNF43 (Ring Finger Protein 43) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CASP8 (Caspase 8) • POT1 (Protection of telomeres 1)

PD-L1 expression • TP53 mutation • TMB-H • MET amplification • MET exon 14 mutation • CDK4 amplification • RNF43 mutation • IDO1 expression • IFNG expression • MET D1028N

PD-L1 IHC 22C3 pharmDx • MI Tumor Seek™

almost2years

MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC): An Analysis by Speciﬁc Mutation, Histology, and Smoking Status (IASLC-TTLC 2023)

"While METex14 is detected in both squamous and non-squamous NSCLC, there are differences in the enrichment of oncogenic pathways, which may explain the heterogeneity in response to various treatments. Future studies investigating specific METex14 alterations may allow more granular personalization of treatment for patients with METex14 NSCLC."

almost 2 years ago

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • KMT2D (Lysine Methyltransferase 2D) • POT1 (Protection of telomeres 1)

PD-L1 expression • TMB-H • MET exon 14 mutation • MET D1028N

PD-L1 IHC 22C3 pharmDx • MI Tumor Seek™

over2years

MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History (IASLC-WCLC 2022)

Within METex14 NSCLC, there is significant variability, with heterogeneity in co-mutations, TMB, and PD-L1 expression across distinct METex14 mutations. METex14 occurs in both squamous and non-squamous NSCLC, but there are differences in co-mutations and outcomes by histology. HLA-G mRNA expression is lower in smokers compared to non-smokers.

over 2 years ago

Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase)

PD-L1 expression • TP53 mutation • TMB-H • MET exon 14 mutation • MET D1028N

PD-L1 IHC 22C3 pharmDx

over2years

Analysis of MET exon 14 skipping mutations in non–small cell lung cancer (NSCLC) by histology and specific mutation. (ASCO 2022)

There is significant heterogeneity within METex14 NSCLC with differences in co-mutations, TMB, and PD-L1 expression noted among different METex14 mutations. While METex14 is detected in both squamous and non-squamous NSCLC, there are differences in enrichment of oncogenic pathways. The clinical impact of these differences warrants further investigation.

over 2 years ago

PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • KMT2D (Lysine Methyltransferase 2D)

PD-L1 expression • TP53 mutation • TMB-H • MET exon 14 mutation • MET mutation • MET D1028N

PD-L1 IHC 22C3 pharmDx